Amylyx Pharmaceuticals Etf Alpha and Beta Analysis
| AMLX Etf | USD 5.34 0.15 2.89% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Amylyx Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Amylyx Pharmaceuticals over a specified time horizon. Remember, high Amylyx Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Amylyx Pharmaceuticals' market risk premium analysis include:
Beta 1.22 | Alpha 1.29 | Risk 5.64 | Sharpe Ratio 0.27 | Expected Return 1.5 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Amylyx |
Amylyx Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Amylyx Pharmaceuticals market risk premium is the additional return an investor will receive from holding Amylyx Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Amylyx Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Amylyx Pharmaceuticals' performance over market.| α | 1.29 | β | 1.22 |
Amylyx Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Amylyx Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Amylyx Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Amylyx Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Amylyx Pharmaceuticals etf reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Amylyx Pharmaceuticals shares will generate the highest return on investment. By understating and applying Amylyx Pharmaceuticals etf market price indicators, traders can identify Amylyx Pharmaceuticals position entry and exit signals to maximize returns.
Amylyx Pharmaceuticals Return and Market Media
The median price of Amylyx Pharmaceuticals for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 3.26 with a coefficient of variation of 36.7. The daily time series for the period is distributed with a sample standard deviation of 1.41, arithmetic mean of 3.83, and mean deviation of 1.24. The Etf received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Milne George M Jr of 100000 shares of Amylyx Pharmaceuticals at 2.198 subject to Rule 16b-3 | 09/03/2024 |
2 | Acquisition by Firestone Karen of 50000 shares of Amylyx Pharmaceuticals at 2.1318 subject to Rule 16b-3 | 09/05/2024 |
3 | Acquisition by Frates James M of 40000 shares of Amylyx Pharmaceuticals at 2.5342 subject to Rule 16b-3 | 09/12/2024 |
4 | Disposition of 1857 shares by Joshua Cohen of Amylyx Pharmaceuticals at 1.57 subject to Rule 16b-3 | 09/23/2024 |
5 | Disposition of 8709 shares by Gina Mazzariello of Amylyx Pharmaceuticals at 3.1967 subject to Rule 16b-3 | 09/30/2024 |
6 | Amylyx Pharmaceuticals executive sells over 27k in company stock | 10/02/2024 |
7 | Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 | 10/15/2024 |
8 | Why Amylyx Pharmaceuticals Stock Was So Healthy This Week | 10/18/2024 |
9 | Amylyx Pharmaceuticals Buy Rating Reiterated at HC Wainwright | 10/22/2024 |
10 | Amylyx Pharmaceuticals, Inc. Short Interest Down 21.1 percent in October | 10/28/2024 |
11 | Theres No Escaping Amylyx Pharmaceuticals, Inc.s Muted Revenues Despite A 81 percent Share Price Rise | 11/04/2024 |
12 | Acquisition by Justin Klee of 63690 shares of Amylyx Pharmaceuticals at 1.57 subject to Rule 16b-3 | 11/06/2024 |
13 | Amylyx Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ... | 11/08/2024 |
14 | Crude Oil Rises Sharply US Homebuilder Sentiment Surges In November | 11/18/2024 |
15 | Goldman Sachs reiterates Neutral on Amylyx stock, target unchanged amid PBH market uncertainties | 11/21/2024 |
About Amylyx Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Amylyx or other etfs. Alpha measures the amount that position in Amylyx Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Amylyx Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Amylyx Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amylyx Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Amylyx Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Amylyx Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Amylyx Pharmaceuticals' management manipulating its earnings.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Amylyx Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.